News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
At present 18 per cent of the local pharmaceutical market is under government's price control
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The trial will be conducted across eight sites in Maharashtra
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The trial will be conducted across 10 sites in India
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Subscribe To Our Newsletter & Stay Updated
